返回 Agendas
Session 2C: Clinical Track: Cardio/Metabolic
Session Chair(s)
Sotirios Tsimikas, MD
Senior Vice President, Global Cardiovascular Development
Ionis Pharmaceuticals, United States
This session will review early to late stage clinical development for two oligonucleotide technologies, aptamers and antisense therapeutics, being developed in the cardiovascular and metabolic therapeutic areas. The targets and applications range from Factor IXa antagonism in the coagulation pathway using an aptamer technology to antisense and antisense GalNAc conjugates to knockdown several independent lipid cardiovascular risk factors.
Speaker(s)
Phase 3 Evaluation of Revolixys Kit: Study Summary and Lessons Learned
Christopher P. Rusconi, PHD
Regado Biosciences Inc., United States
Chief Scientific Officer; Senior Vice President Discovery/Preclinical Developmen
Antisense Therapies for Unmet Clinical Needs in Lipid Disorders: ApoC-III, Lp(a) and ANGPTL3
Sotirios Tsimikas, MD
Ionis Pharmaceuticals, United States
Senior Vice President, Global Cardiovascular Development
PCSK9
Pushkal Garg
Alnylam Pharmaceuticals, Inc., United States
Panel Discussion
All Session Speakers, United States